Literature DB >> 17649772

Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations.

Elena S Gershtein1, Alexander M Scherbakov, Valentina A Shatskaya, Nicolai E Kushlinsky, Mikhail A Krasil'nikov.   

Abstract

BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/Akt signalling pathway plays a major role in the regulation of breast cancer growth and survival, but the clinical value of its components in human tumours is unclear. PATIENTS AND METHODS: PI3K was analysed using Western blotting with monoclonal antibodies to the p85 subunit in tumour and adjacent mammary gland samples from 33 breast cancer patients. Activated Akt1 (pAkt1) expression was quantified in 46 sample pairs by a direct sandwich ELISA assay.
RESULTS: Tumour PI3K expression was increased in 79% of the investigated sample pairs and was not associated with the main clinico-pathological features. Only 49% of breast cancers had increased pAkt1, but the frequency of its elevation was positively associated with tumour size and histological grade, and controversially related to estrogen and progesterone receptor status.
CONCLUSION: Increased PI3K but not pAkt1, expression appears to be a widespread feature of human breast cancer indicating the different roles of the two components of one signalling system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17649772

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.

Authors:  Kitty Pavlakis; Mattheos Bobos; Anna Batistatou; Vassiliki Kotoula; Anastasia G Eleftheraki; Anastasios Stofas; Eleni Timotheadou; George Pentheroudakis; Amanda Psyrri; Angelos Koutras; Dimitrios Pectasides; Pavlos Papakostas; Evangelia Razis; Christos Christodoulou; Konstantine T Kalogeras; George Fountzilas
Journal:  Pathol Oncol Res       Date:  2014-08-08       Impact factor: 3.201

Review 2.  Ceramides as modulators of cellular and whole-body metabolism.

Authors:  Benjamin T Bikman; Scott A Summers
Journal:  J Clin Invest       Date:  2011-11-01       Impact factor: 14.808

3.  Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.

Authors:  Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

Review 4.  Tumor mechanics and metabolic dysfunction.

Authors:  Jason C Tung; J Matthew Barnes; Shraddha R Desai; Christopher Sistrunk; Matthew W Conklin; Pepper Schedin; Kevin W Eliceiri; Patricia J Keely; Victoria L Seewaldt; Valerie M Weaver
Journal:  Free Radic Biol Med       Date:  2014-12-19       Impact factor: 7.376

5.  Oleanolic acid derivatives induce apoptosis in human leukemia K562 cell involved in inhibition of both Akt1 translocation and pAkt1 expression.

Authors:  Shuhua Pan; Jun Hu; Tingting Zheng; Xinyuan Liu; Yong Ju; Chuanlian Xu
Journal:  Cytotechnology       Date:  2014-04-12       Impact factor: 2.058

6.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

7.  Design, Synthesis and Biological Evaluation of Neocryptolepine Derivatives as Potential Anti-Gastric Cancer Agents.

Authors:  Yunhao Ma; Yanan Tian; Zhongkun Zhou; Shude Chen; Kangjia Du; Hao Zhang; Xinrong Jiang; Juan Lu; Yuqing Niu; Lixue Tu; Jie Wang; Huanxiang Liu; Hongmei Zhu; Peng Chen; Yingqian Liu
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

8.  NEDL2 regulates enteric nervous system and kidney development in its Nedd8 ligase activity-dependent manner.

Authors:  Xiao Qiu; Rongfei Wei; Yang Li; Qiong Zhu; Cong Xiong; Yuhan Chen; Yuan Zhang; Kefeng Lu; Fuchu He; Lingqiang Zhang
Journal:  Oncotarget       Date:  2016-05-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.